October 2019

Allievex Corporation Enters Licensing Agreement With BioMarin Pharmaceutical

United States - Massachusetts

Faegre Drinker represented Allievex Corporation, a biopharmaceutical company based in Boston, Massachusetts, in connection with the in-licensing from BioMarin Pharmaceutical Inc. of exclusive worldwide rights to develop and commercialize an enzyme replacement therapy to treat mucopolysaccharidosis type IIIB (MPS IIIB), a rare pediatric neurodegenerative disease.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.